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SUPPLEMENTARY METHOD 1: Purification of recombinant IGF-I analogues. 
 
The expressed IGF-I protein (along with other expressed proteins) within the 
conditioned media of SF9 cells was precipitated with 30% w/v polyethylene glycol 
(PEG) 6000 overnight at 4 °C. The protein pellet was resuspended in buffer A (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole pH 8.0) and loaded onto a 2 mL 
Ni
2+
-NTA Superflow agarose column equilibrated with buffer A. The column was 
washed with 20 mM imidazole buffer and eluted across a 20-250 mM imidazole 
gradient at a flow rate of 1 mL per min. Fractions demonstrating IGF-I 
immunoreactivity were pooled and reprocessed on a second Ni
2+
-NTA Superflow 
agarose column. After processing as above, fractions showing IGF-immunoreactivity 
with >90% purity were pooled. To remove imidazole and the remaining peptide 
impurities, fractions pooled from the second Ni
2+
-NTA run were diluted with 0.1% 
trifluoroacetic acid and adjusted to pH 1.0 - 2.0. The load fraction (~40 mL) was 
passed onto a 250 mm x 10 µm C4, 5 µm reversed phase HPLC column (Vydac, 
USA) and pre-equilibrated with 0.1% trifluoroacetic acid. The bound proteins were 
then eluted using 0 to 100% 0.1% trifluoroacetic acid/80% acetonitrile at 2 mL per 
minute. IGF-I positive fractions were subsequently stored prior to use. 
 
SUPPLEMENTARY METHOD 2: In-gel digestion.  
 
Excised bands from Coomasie-stained SDS-PAGE gels were washed with water and 
destained (2 washes in 200 μL 50 mM NH4HCO3 in 50% AcN; 30 min each). 
Samples were reduced (10 mM dithiothreitol (DTT) in 50 mM NH4HCO3, 37°C, 30 
min) and alkylated (50 mM iodoacetamide, 50 mM NH4HCO3, RT, 60 min). The 
plugs were dehydrated in 200 μL AcN for 10 min and rehydrated overnight at 37 °C 
with 20 μL of 12.5 μg/mL chymotrypsin (Roche Diagnostics; Castle Hill, NSW, 
Australia) suspended in 100 mM Tris-HCl and 10 mM CaCl2 (pH 7.8). The peptides 
were extracted twice in 20 μL 5% formic acid/50% AcN, evaporated to dryness and 
resuspended in 10 µL 2% formic acid. LC-MS/MS on these digested peptides was 
performed using a Shimadzu Prominence nano-HPLC interfaced with an AB SCIEX 
TripleTOF 5600 system, fitted with a nanospray ion source and running Analyst TF 
(version 1.5.1). 
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SUPPLEMENTARY FIGURE 1. Organisation and sequence information of IGF-I 
expression construct. The nucleotide (A) and corresponding protein sequence (B) of 
the wtIGF-I expression cassette inserted within the pIB vector is illustrated. 
Nucleotides and amino acids are colour coded to denote their respective coding 
moieties. The arrows highlight lysine sites at positions 27, 65 and 68 within the IGF-I 
mature peptide sequence. 
 
 
 
 
 
SUPPLEMENTARY FIGURE 2. Expression and purification of expressed IGF-I 
analogues. Coomassie staining was performed on equal concentrations (50 ng) of C4 
pure IGF-I analogues with rIGF-I as control (A). The concentrations of rIGF-I used 
are marked as 50 ng and 100 ng. IGF-I reactive fractions from the second Ni
2+
-NTA 
run were further purified using C4 FPLC and the final product (R68 shown) was 
assessed post-protein quantification at indicated concentrations with rIGF-I as control 
(B). 
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SUPPLEMENTARY FIGURE 3. Mass spectra of R65/68-IGF-I and R27/65/68-
IGF-I analogues. A) Illustration of the mass spectrum of wtIGF-I B) Illustration of 
the mass spectrum of R68-IGF-I. 
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SUPPLEMENTARY FIGURE 4. Mass spectra of R65/68-IGF-I and R27/65/68-
IGF-I analogues. A) Mass spectrum of R65/68-IGF-I illustrates two deletion species, 
9,179 Da (-RSA) and 9,335 Da (-SA), in addition to the genuine R65/68-IGF-I full-
length construct at 9,494 Da. B) Mass spectrum of R27/65/68-IGF-I illustrates two 
deletion species, 9,207 Da (-RSA) and 9,363 Da (-SA), in addition to the genuine 
R27/65/68-IGF-I full-length construct at 9,522 Da.  
 
 
 
 
 
SUPPLEMENTARY FIGURE 5. Cross-linking of IGF-I analogues to Q peptide in 
the presence of FXIIIa. Cross-linking of IGF-I constructs to glutamine acceptor 
substrate, Q peptide was performed in the presence of 0.75 units of FXIIIa in 20 µL 
reaction volume at 37 °C for 30 min. All the cross-linking reactions with expressed 
IGF-I constructs were compared with control reactions containing rIGF-I on 4-12% 
SDS-PAGE gel.  
 
 
 
IGF-I* in A = wtIGF-I 
IGF-I* in B = R27-IGF-I 
IGF-I* in C = R27/65-IGF-I 
IGF-I* in D = R27/65/68-IGF-I 
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SUPPLEMENTARY FIGURE 6. Cross-linking of recombinant IGF-I to Q 
peptide. Mass spectrum of ‘rIGF-I only’ showed a peak at 7,647 Da (A). Cross-
linking of rIGF-I to Q peptide was demonstrated by the peak observed in the mass 
spectrum at ~8,897 Da in the presence of FXIIIa (B) and in the presence of TG2 (C). 
 
 
 
 
  
IGF-I*1 in E = R65-IGF-I 
IGF-I*2 in E = R68-IGF-I 
 
 
IGF-I*1 in F = R65/68-IGF-I 
IGF-I*2 in F = R27/68-IGF-I 
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SUPPLEMENTARY FIGURE 7. Cross-linking of recombinant IGF-I to Q peptide 
in the presence of TG2. Cross-linking of IGF-I constructs to glutamine acceptor 
substrate, Q peptide, was performed in the presence of 0.75 units of TG2 in 20 µL 
reaction volume at 37 °C for 30 min. All the cross-linked reactions with expressed 
IGF-I constructs were compared with control reactions containing rIGF-I resolved on 
a 4-12% SDS-PAGE gel 
 
 
 
 
 
 
 
 
 
IGF-I* in A = wtIGF-I 
IGF-I* in B = R27-IGF-I 
IGF-I* in C = R27/65-IGF-I 
IGF-I* in D = R27/65/68-IGF-I 
IGF-I*1 in E = R65-IGF-I 
IGF-I*2 in E = R68-IGF-I 
 
 
IGF-I*1 in F = R65/68-IGF-I 
IGF-I*2 in F = R27/68-IGF-I 
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SUPPLEMENTARY TABLE 1. Sequence information of the primer sequences used 
for the creation of KR IGF-I analogues. P denotes phosphorylation of the primers at 
the 5´ end. 
 
Primer Name  Sequence (5’-3’)  
K27 sense  
P
GTTACGGTTCCTCCTCTCG 
K27 antisense  CGGTGGGACGGTTGAAGTAG 
K65 sense  
P
CGTCCTGCTAAGTCCGC 
K65 antisense  CAGGGGAGCGCAGTAC 
K68 sense  
P
CGTTCCGCTTAACTCG 
K68 antisense  AGCAGGCTTCAGGGGAG 
 
 
